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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S171-7.5 to -2.0], P¼0.001), total body fat mass (MD: D vs. E; -4.6 kg [CI -7.0 to
-2.2], P¼0.0002), and leg fat mass (MD: D vs. E; -1.7 kg [CI -2.6 to -0.8],
P¼0.0003) compared to Group D, there were no statistically signiﬁcant
differences between Groups E and C in either body composition outcomes
(P>0.15).
Conclusions: This study do not support the hypothesis that exercise
maintenance programmes provides added beneﬁts in muscle strength and
lean mass compared to dietetic counselling or even a no attention control
after 1 year. This study outcome may be due to poor training compliance.
Dietetic counselling resulted in greater total body weight loss and lower
percentage lean mass loss compared to exercise and control. These results
suggest dietetic counselling as a primary maintenance treatment option to
uphold beneﬁcial effects of an initial weight loss on body mass and
composition.
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DICLOFENAC NOT MORE EFFECTIVE THAN ACETAMINOPHEN IN
PATIENTS WITH MILD KNEE OSTEOARTHRITIS: RESULTS OF
A RANDOMIZED CONTROLLED TRIAL IN PRIMARY CARE WITH A 12-
WEEK FOLLOW-UP
S.P. Verkleij, P.A. Luijsterburg, B.W. Koes, A.M. Bohnen,
S.M. Bierma-Zeinstra. Erasmus MC, Rotterdam, Netherlands
Purpose: Guidelines for knee osteoarthritis (OA) recommend acetamino-
phen as the medication of ﬁrst choice when pain medication is needed,
based on safety and suggested effect of acetaminophen in mild stages of
OA. However, in clinical practice, non-steroidal anti-inﬂammatory drugs
(NSAIDs) are still widely used as ﬁrst prescribed medication. This might be
based on the lack of direct comparisons of acetaminophen and NSAIDs in
ﬁrst-time medication users Therefore, we assessed the effectiveness of
Diclofenac versus acetaminophen, regarding improvement in pain, in
patients with mild knee OA who consulted their GP and were willing to
start pain medication.
Methods: This pragmatic open-label RCT, with a 12-weeks follow-up
period, included patients who consulted their GP with a new episode of
knee pain, aged 45 years and older, with a pain severity score of two or
higher on an 11-point numeric rating scale (NRS), and whomet the clinical
American College of Rheumatology (ACR) criteria for knee OA. Patients
were randomly allocated to either Diclofenac (maximum daily dose of 150
mg.) or acetaminophen (maximum daily dose of 3000 mg.) for 2-weeks
and if required an additional 1-2 weeks, which is close to usual care.
During the 12-week follow-up period, patients ﬁlled out a daily diary tomeasure knee pain severity and medication intake. Subsequently, patients
ﬁlled out questionnaires at baseline, 3, 6, 9, and 12-weeks. Primary
outcomes were 4-weeks daily knee pain severity measured with a NRS
collected with a diary, and 3-weekly knee pain severity over the 12-weeks
period measured with an NRS and the Knee Injury and Osteoarthritis
Outcome Score (KOOS) collected from the questionnaires. The secondary
outcome was daily medication intake. Generalized estimated equations
(GEE) analyses were used, according to the intention to treat principle, to
assess differences between the groups and adjusted for age, gender, and
baseline pain differences.
Results: A total of 104 patients were randomized to either Diclofenac
(n¼52) or acetaminophen (n¼52). At baseline, mean knee pain severity
was 5.1 (SD: 1.8) for the acetaminophen and 5.4 (SD: 2.1) for the Diclofenac
group. At day 1 from the diary, mean knee pain severity was 4.3 (SD: 1.8)
for acetaminophen and 4.9 (SD: 1.9) for Diclofenac. Although there seems
to be a slightly stronger reduction in knee painwithin the ﬁrst 2-weeks for
Diclofenac users, differences in knee pain over the ﬁrst 4-weeks between
the groups were not statistically signiﬁcant (b: 0.1; 95% CI: -0.7 to 0.9).
Over 12-weeks, no statistically differences were found between the groups
knee pain severity measured with KOOS (b: -3.1; 95% CI: -9.7 to 3.5) and
the NRS (b: -0.24; 95% CI: -1.1 to 0.6). Also, we found no signiﬁcant
differences between the groups regarding total medication intake (OR: 1.4;
0.6 to 3.0). After 4-weeks in the Diclofenac group, 18 patients still used
Diclofenac, 6 patients used acetaminophen, one ibuprofen, and 21 patients
stopped taking medication. After 4-weeks in the acetaminophen group, 16
patients still used acetaminophen, 1 patient used both acetaminophen and
Celebrex, and 24 stopped their medication.
Conclusions:We found no difference in effectiveness between Diclofenac
vs. acetaminophen in reducing pain in patients with mild knee OA. These
results endorse the recommendation of acetaminophen as 'ﬁrst choice
medication' in (inter)national guidelines regarding primary care patients
with knee OA.
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PLASMA RICH IN GROWTH FACTORS (PRGF-ENDORET) IN THE
TREATMENT OF SYMPTOMATIC KNEE OSTEOARTHRITIS:
A RANDOMIZED CLINICAL TRIAL
M. Sánchez 1, E. Anitua 2, N. Fiz 1, J. Azofra 1, J. Usabiaga 3, E. Albillos 3,
A. Garcia 3, J. Albillos 4, R. Garate 4, A. JJ 5, S. Padilla 2, G. Orive 2. 1UCA,
Vitoria, Spain; 2BTI Biotechnology Inst. ImasD, S.L. C/ Jacinto Quincoces, 39
01007 Vitoria (Spain)., Vitoria, Spain; 3Hosp. Donostia. Paseo Doctor
Begiristain 115. San Sebastián- Donostia (Spain)., San Sebastian, Spain;
4 Policlínica Guipúzcoa. Paseo Miramón 174. San Sebastián- Donostia
(Spain)., San Sebastian, Spain; 5 bti Biotechnology Inst. ImasD, S.L. C/
Jacinto Quincoces, 39 01007 Vitoria (Spain)., Vitoria, Spain
Purpose: This multicenter, double-blind, hyaluronic acid-controlled clin-
ical trial evaluated the efﬁcacy and safety of PRGF-Endoret, an autologous
biological therapy for regenerative purposes, as a treatment for knee pain
from osteoarthritis.
Methods: We randomly assigned 176 patients with symptomatic knee
osteoarthritis to receive inﬁltrations with PRGF-Endoret or with hyaluronic
acid (three injections on a weekly basis). The primary outcome measure
was a 50 percent decrease in knee pain from baseline to week 24. We also
assessed pain, stiffness, and physical function using theWOMAC Index; the
rate of response using the criteria of the OMERACT-OARSI; and safety.
Results: The mean age of the patients was 59.8 years, and 52 percent were
women. As compared with the rate of response to hyaluronic acid, the rate
of response to PRGF-Endoret was 14.1 percentage points higher (P¼0.044).
Regarding the secondary outcome measures, the rate of response to PRGF-Endoret was in all the cases higher, although no signiﬁcant differences
were reached. For patients with moderate to severe pain at baseline, the
rate of response to PRGF-Endoret was 26 percentage points higher
(P¼0.086) than the rate of response to hyaluronic acid, although no
signiﬁcant differences were reached. Adverse events were mild and evenly
distributed among the groups.
Conclusions:PRGF-Endoret has both a faster time to response and more
enduring beneﬁcial effect than hyaluronic acid. Treatment with PRGF-
Endoret resulted in clinically signiﬁcant reductions in knee pain, stiffness
and physical function, with mild adverse effects, in patients with knee
osteoarthritis. (ClinicalTrials.gov number, NCT00782197).
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A PROSPECTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND
FEASIBILITY STUDY TO EVALUATE THE SAFETY AND PERFORMANCE
OF HYDROS JOINT THERAPY AND HYDROS-TA JOINT THERAPY FOR
MANAGEMENT OF PAIN ASSOCIATED WITH OSTEOARTHRITIS IN THE
KNEE
R.J. Petrella 1,2, P. Eamans 3, J. Alleyne 4,5, M. Maroney 6. 1U Western Ontario,
London, ON, Canada; 2 Lawson Hlth.Res. Inst., London, ON, Canada;
3Maastricht Univ. Med. Ctr., Maastricht, Netherlands; 4Univ. of Toronto,
Toronto, ON, Canada; 5Women's Coll. Hosp., Toronto, ON, Canada;
6Carbylan BioSurgery, Palo Alto, CA
Purpose: Carbylan Osteoarthritis Research 1.0 (COR 1.0) was a prospective,
multicenter, randomized, double-blind feasibility study to evaluate the
safety and performance of Hydros Joint Therapy (Hydros) and Hydros-TA
Joint Therapy (Hydros-TA) in subjects with Kellgren&Lawrence grade 2 and
3 osteoarthritis (OA) of the knee.
Methods: A total of 98 subjects were enrolled, treated, and followed for six
months post-treatment. Subjects were randomized 1:1:1 to Hydros (PEG
cross linked HA without TA), Hydros-TA (PEG cross linked HA with TA), or
Synvisc-One Hylan G-F 20 (Synvisc-One).
Hydros is a bioresorbable hyaluronan-based hydrogel suspended in
a hyaluronan solution. Hydros-TA incorporates a low dose (10mg) corti-
costeroid, triamcinolone acetonide, suspended within the hyaluronan
hydrogel, and is designed to retain steroid locally in the joint.
All randomized subjects received one 6 mL intra-articular (IA) injection in
the treatment knee by an unblinded injecting physician. The treatment
knee was the knee that met the inclusion criteria on the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) A (pain)
subscale score (50-90mm on 100mm VAS). Subjects and evaluating
physicians who followed subjects post-treatment were blinded to
treatment.
Subjects were seen by a treatment-blinded evaluating physician for post-
treatment follow-up at 2 weeks, 6 weeks, 13 weeks, and 26 weeks.
Subjective symptom rating and physical assessment including the full
WOMAC questionnaire were obtained at screening and each follow-up
visit. Subject global assessment was obtained at 13 weeks and subject and
physician global assessments were obtained at 26 weeks. Adverse events
were solicited at all visits.
The primary efﬁcacy endpoint was the time-weighted change from base-
line in the WOMAC A (pain) subscale average score for the treatment knee
over 26 weeks. Differences between treatment were assessed using an
analysis of covariance (ANCOVA) model.
Results: For the primary outcome, Hydros demonstrated a 41.2mm
reduction, Hydros-TA demonstrated a 42.2mm reduction and Synvisc-One
demonstrated a 37.5mm reduction from baseline pain. These results rep-
resented an improvement of 3.7mm and 4.7mm over Synvisc-One for
Hydros and Hydros-TA respectively. Greater reductions in pain for Hydros-
TA vs Synvisc-One were observed at all timepoints over the course of the
study.
The percentage of subjects who responded favorably to the product (as
measured by the OMERACT-OARSI responder rate) was also higher in the
Hydros and Hydros-TA groups when compared to Synvisc-One. Hydros-
TA showed a trend towards a faster onset of pain relief compared to the
non-steroid containing products evaluated in the study. Hydros-TA
provided a 43.5mm mean reduction from baseline pain at the 2 week
time point compared to a mean reduction of 37.7mm and 32.3mm for
Synvisc-One and Hydros, respectively. In the Hydros-TA treatment group
